Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daima Bukini has a total of 147 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    "I know that one day I will be cured": Perspectives on acceptability of curative therapies for sickle cell disease in Tanzania.

    by Daima Bukini, Kassim Kassim, Collins Kanza, Aisha Rifai, Rahma Chanzi, Augostino Amando, Elianna Amin, Jonathan Spector, Julie Makani

    While curative treatments for sickle cell disease (SCD), including hematopoietic stem cell transplant and gene therapies are largely restricted to high-resource settings, recent advancements have raised hopes that they will eventually become more accessible to patients in Africa, where the disease is particularly prominent and contributes to substantial morbidity and mortality. Understanding the factors that influence acceptability of curative therapies will therefore be important in developing strategies for successful adoption and implementation. To address this need, a qualitative study was conducted to gain insights into the perspectives of patients and families in Tanzania regarding curative therapies for SCD, focusing on factors affecting treatment acceptability. A total of 81 individuals (46 caregivers and 35 patients) participated in Focus Group Discussions or In-Depth Interviews; the majority were female (67%) and between 21 and 40 years of age. The results indicated substantial interest in current and prospective curative programs, with various factors influencing the attitudes of patients and caregivers differently. The findings suggested that caregivers' decisions were likely to be influenced by the burden of caregiving roles and the financial costs related to care for SCD. Patients were more likely to accept the therapies if provided with information on safety of the therapies and transparency of data from treated patients. In preparation for GT trials or transplants, tailored engagement strategies for patients younger than 18 years old will be necessary as the majority of SCD patients in Africa are children. Healthcare professionals must be well-informed to address questions and concerns from patients' families. Overall, the study highlighted strong interest in curative therapies for SCD in Tanzania while identifying important factors shaping acceptability, underscoring the need for tailored engagement and early involvement of affected families in program planning.

  • Open Access

    I know that one day I will be cured, and all will be well: Perspectives on acceptability of curative therapies for sickle cell disease in Tanzania.

    by Daima Bukini, Kassim Kassim, Collins Kanza, Aisha Rifai, Rahma Chanzi, Augostino Amando, Elianna Amin, Jonathan Spector, Julie Makani

    While curative treatments for sickle cell disease (SCD) including hematopoietic stem cell transplant and gene therapies are largely restricted to high-resource settings, recent advancements have raised hopes that they will eventually become more accessible to patients in Africa, where the disease is particularly prominent and contributes to substantial morbidity and mortality. Understanding the factors that influence acceptability of curative therapies will therefore be important in developing strategies for successful adoption and implementation. To address this need, a qualitative study was conducted to gain insights into the perspectives of patients and families in Tanzania regarding curative therapies for SCD, focusing on factors affecting treatment acceptability. A total of 81 individuals participated through Focus Group Discussions or In-Depth Interviews. The results indicated substantial interest in current and prospective curative programs, with various factors influencing the attitudes of patients and caregivers differently. Study findings suggested, caregivers decisions were likely to be influenced by the burden of caregiving roles and the financial costs related to care for SCD. Patients were likely to accept the therapies if provided with information on safety of the therapies and requested for transparency of data from treated patients. In preparation for gene therapy trials or transplants, tailored engagement strategies for patients younger than 18 years old will be necessary as majority of SCD patients in Africa are children. Healthcare professionals must be well-informed to address questions and concerns from patients families. Future efforts should incorporate early involvement of patients and caregivers in Africa in programs related to curative therapies for SCD.


  • Open Access

    Combining deliberative engagement with qualitative research to assess patient and caregiver perspectives on curative therapies for sickle cell disease in Africa

    by Daima Bukini, Jennifer Mashaka, Aisha Rifai, Collin Kanza, Kassim Kassim, Rahma Chanzi, Deogratius Maingu, Frederick Luoga, Winfrida Lema, Fatou Konteh, et al.

    The vast majority of individuals impacted by sickle cell disease (SCD) live in Africa, where access to potentially curative therapies such as hematopoietic stem cell transplant and gene therapies have been severely limited until now. As part of a broad effort to help prepare scientific, healthcare, and patient communities in Tanzania for the introduction of advanced SCD therapies, we sought to understand perspectives relating to curative options for SCD held by patients and their families. To achieve this, innovative qualitative research methodology was required given the highly variable level of baseline knowledge among patient communities regarding curative treatments for SCD. We therefore adopted an approach of deliberative engagement followed by traditional qualitative methods that facilitated successful identification of participants, development of research tools, and, ultimately, elicitation of valuable insights that enabled in-depth analyses. Our experience demonstrates that, when exploring perspectives relating to complex medical procedures in this population, deliberative engagement substantially enhances the outputs of qualitative research.

  • Open Access

    Strengthening global partnerships for sustainable sickle cell disease care: insights from SickleInAfrica at the 77th United Nations General Assembly and the US-Africa Leaders’ Summit

    by Irene Kida Minja, Siana Nkya, Daima Bukini, Nesia Mahenge, Upendo Masamu, Janeth Manongi, Josephine Mgaya, Frank Mtiiye, Malula Nkanyemka, Eka Patricia Kisali, et al.

    Background: Addressing sickle cell disease (SCD) is crucial for achieving health-related Sustainable Development Goals, particularly in Africa. The region is significantly affected, with 78.7% of patients with SCD residing in sub-Saharan Africa and over 515 000 newborns diagnosed annually. Historically, African health systems have struggled to provide optimal care for patients with SCD, resulting in high under-5 mortality and severe childhood morbidity. Scientific innovations and stakeholder engagement offer hope for improving SCD outcomes. Objective: To explore the role of high-level partnerships and scientific innovation in advancing SCD care and research in Africa, focusing on the contributions and strategic engagements of the SickleInAfrica, as highlighted at the 77th United Nations General Assembly (UNGA) and the US-Africa Leaders’ Summit. Approach: SickleInAfrica, comprising eight countries, leverages a robust infrastructure for SCD research and care. The consortium has established a comprehensive SCD database and a patient registry in each of the consortium sites that includes demographic details, clinical diagnosis, management details and follow-ups/visits. Currently, over 34 000 patients with SCD are enrolled, making it the largest globally. It has also contextually adapted clinical guidelines for managing SCD for all levels of care. The high-level engagements at the 77th UNGA held in September 2022 in New York and the US-Africa Leaders’ Summit held in December 2022 in Washington DC promoted SCD awareness and partnerships. The UNGA session emphasised biomedical science, implementation research and partnerships in therapeutic development, while the US-Africa Leaders’ Summit session focused on Global Partnerships for SCD: Advancing Science and Technology for Health in Africa. Conclusions: High-level engagements facilitate cross-border dialogues, underscoring the importance of partnerships from grassroots to global alliances. Key outcomes include increased awareness, policy advocacy and the establishment of SCD Centres of Excellence and genomics capacity-building initiatives. Sustainable efforts require robust partnerships, government involvement, community awareness and equitable access to advanced therapies.


  • Open Access

    Responsible governance of genomics data and biospecimens in the context of broad consent: experiences of a pioneering access committee in Africa

    by Ahmed Rebai, Akin Abayomi, P Andanda, R Kerr, Kobus Herbst, J Mabuka, R Wamuyu, Daima Bukini, C Dandara

    International collaboration in genomic research is gaining momentum in African countries and is often supported by external funding. Over the last decade, there has been an increased interest in African genomic data. The contribution of this rich data resource in understanding diseases predominant in both African and global populations has been limited to date. There has been some non-governmental funding dedicated to the advancement of genomic research and innovation by African-based and African-led research groups, but the impact of these initiatives is hard to quantify. However, there is now an opportunity for the global research community to leverage decades of genomic data and biospecimens originating from African populations. The experience we describe in this paper is of an access governance framework established under the Human, Heredity, and Health in Africa (H3A) consortium, given the task of managing wider access to the data and biospecimen resources collected via its various projects. The function of the Data and Biospecimen Access Committee (DBAC) is to facilitate the advancement of medicine and health while fostering the development of bioinformatics capabilities at Africa-based institutions or regional hubs. Our collective experiences and lessons learnt as a committee provide examples of nuanced considerations when evaluating access to African data. The committee was semi-autonomous in its establishment and had independence in decision-making. The DBAC continually advocates for the responsible use of genomic data and biospecimens that were obtained from African research participants, under broad consent, by primary researchers who no longer have oversight over the future use of these resources.


  • Open Access

    Strengthening advanced therapy for sickle cell disease in Africa: experience from sickle cell disease centre in Dar es Salaam, Tanzania

    by Daima Bukini, Aisha Rifai, Collin Kanza, Fredrick Luoga, Deogratius Maingu, Kassim Kassim, Jennifer Mashaka, Eka Patricia Kisali, Salmaan Karim, Mohamed Zahir Alimohamed, et al.

    Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps remain in advanced treatments for SCD. To help address this burden, Tanzania has established one of the largest single-centre SCD programmes in the world and developed an advanced therapy programme for SCD focused on patient engagement and advocacy, clinical activities involving exchange blood transfusion (ExBT) and haematopoietic stem cell transplant (HSCT), gene therapy (GT) preparedness, and enabling partnerships. This report describes the programme’s genesis, structure and progress achieved. Patient engagement camps and patient-focused workshops conducted since early 2021 have involved more than 150 patients, family caregivers and healthcare providers. A patient registry was established by screening 1500 patients eligible for advanced therapies with 157 identified to benefit from advanced treatments for SCD. Out of which 22 patients received ExBT, and human leucocyte antigen typing was conducted on 127 individuals to establish a registry of family members with potential to be HSCT donors. Target product profiles were devised for minimum and optimum criteria of GT products to guide drug discovery and development efforts, and qualitative research was conducted to investigate factors anticipated to influence successful adoption of GTs for SCD in Africa. The programme’s multifaceted components have been enabled by institutional networks and collaborations established at national, regional and global levels. The programme presented opportunities to deliver cost-effective advanced treatment and curative options for SCD in Tanzania and lessons learnt may be applicable to inform similar efforts in other African regions where SCD is highly endemic.


  • Open Access

    Strengthening global health policies, guidance, regulations: responding to calls for public consultation by integrating diverse voices, experience and expertise

    by David R Curry, Sedem Adiabu, Daima Bukini, Lynn Ang, Thalia Arawi, Beate Aurich, Mariam Hassan, Fernando Lolas, Rita S Sitorus, Yeyang Su

    In this open letter, members of the Global Forum for Research Ethics and Integrity [GFREI] – an open, independent collaborative involving 80+ individuals in 30+ countries – report on and extend arguments made during a workshop conducted at the Oxford Global Health and Bioethics International Conference (June 26–27, 2023). Ten GFREI presenters from nine countries used a case study approach to present and discuss an emerging model to integrate diverse global voices in engaging open public consultation opportunities – sometimes termed calls for input, calls for public comment, requests for information (RFIs). A key form of public consultation invites observations and ideas on, and specific edits to, draft versions of policies, guidance, regulations, and other formats under a specific deadline. Based on our experience, we posit that engagement of public consultation opportunities is a matter of transnational civic responsibility; that such engagement can add substantive value to public discourse and the realization of public good; that engaging voices and views from all global regions, and respecting and integrating diverse contributions from varying experience, expertise and forms of knowledge significantly strengthens public consultation responses; and that sustaining and extending GFREI’s independent global voice, and building its diversity and the range of disciplines represented, is worthy of robust support from the global community. Finally, we call on the ethics/bioethics community to engage these calls as an important strategy in advancing the ethical soundness of the laws, regulations, policies, guidelines presented for public consultation.

  • Open Access

    The contribution of social and family networks in supporting care of children with sickle cell disease in Tanzania

    by Daima Bukini, Irene Msirikale, Collins Kanza, Jesca Odengo, Deogratius Maingu, Upendo Masamu, Karim Manji, Julie Makani, Columba Mbekenga

    Background The care of children with Sickle cell disease (SCD) in Africa has been the work of mothers or women within communities. Previous studies have indicated that mothers in these families are supported by other women within the family or even from outside family structures. Such support has allowed significant sharing of responsibilities in both domestic and care giving roles for children with sickle cell disease. However, there is limited recognition of this informal support and its importance as a key element in health care provision. Objective In this paper, we aim to demonstrate how these support networks have been used by mothers in shouldering their caregiving roles. We also propose how the networks can be integrated into the health care system to improve quality of care of the children with SCD. Methods We conducted interviews with families of children who are diagnosed with sickle cell disease through newborn screening program in Tanzania between 2015 and 2019. In total, 15 families were included through focus group discussions (FGDs), dyadic interviews, and individual interviews. Also, a survey was conducted involving 100 families of children with SCD aged between 0 and 17 years to assess the different networks of care that exists within families and communities. Thematic analysis was used for the qualitative data while data from the survey was presented in proportions as pie charts. Results The results from the FGDs and IDIs demonstrated three ways in which the networks of care were supportive to mothers (1) Facilitating sickle cell disease diagnosis to children who were undiagnosed (2) Caring for the sick child (children) after diagnosis and (3) Support at home in caring for other children who are not sick and helping with domestic work responsibilities. Survey results indicated that the highest proportion of the respondents listed mothers of the children as the primary care giver (88%), followed by grandmothers (10%) and close family members (2%). Extended family members (20%) were recognized as the largest network of care in the absence of the primary caregiver outside the parents, followed by siblings, defined as elder brothers and sisters (18%) and grandparents (16%). Conclusion The findings from this study confirm that there is an important network supporting care of children with SCD in communities supporting parents. Enabling these support networks to be more formally integrated into the health care system will ensure those members of the community providing care are equipped with knowledge on sickle cell disease and having positive impact on the quality of care of the children born with SCD in sub-Saharan Africa.


  • Open Access

    Communicating sickle cell trait results after newborn screening: Approaches and implications to families

    by Daima Bukini, Irene Msirikale, Emanuela Marco, Michael Msangawale, Lulu Chirande, Columba Mbekenga, Karim Manji, Julie Makani

    Introduction: Tanzania is amongst the countries in Africa with one of the highest prevalence of individuals with Sickle Cell Trait (SCT). Identifying individuals with SCT is important as they may potentially have children with Sickle Cell Disease (SCD). Interventions such as Newborn Screening (NBS) for SCD can identify individuals carrying the gene very early on to explore strategies for primary prevention. Aim: This study aims to document experiences and perspectives of families who have received SCT results for their children through the NBS Program. We were interested to learn their perspectives on the communication approaches used and implications of the results to families. Our overall goal is to evaluate what approaches works best to support comprehension, understanding of genetic testing, concepts of inheritability and general understanding of SCD. We further aim to explore key issues considered by families as most important to inform not only methods, but also most locally relevant content to guide genetic counselling sessions. Methods: In total 29 families provided with SCT results participated in six (6) Focus Group Discussions. Families were recruited through NBS program implemented between June to September 2021. Analysis of the data was done through thematic content analysis. Results: Findings were categorized into two main categories; ( 1) Key issues to consider when communicating sickle cell trait results to families . The following themes were identified under this category; (1a) Language used to explain the results (1b) Methods used to provide the results (1c) Who was provided with the results (1d) Families comprehension of the results and (1e) What influences families’ understanding of the results (2) What are the implications of the results to families . The following themes were identified under this category; (2a) How results influenced future reproductive choices (2b) How will the information be kept within families (2c) Age a child will start to be informed about the results (2d) How results influence gender blames within families. Conclusion: Understanding how to ensure genetic results have been properly communicated is core in developing a genetic counselling program. In places where the programs are not well established, there is a need to explore contexts specific approaches to inform ethically relevant communication models that incorporated families and patient perspectives. This study un-packed the different aspects to consider when developing proper communication models and further highlighted issues to explore with families after receiving the results, with the hope that this information will help to inform genetic counselling sessions in places with high SCD burden.


  • Open Access

    Perspectives on Building Sustainable Newborn Screening Programs for Sickle Cell Disease: Experience from Tanzania

    by Daima Bukini, Siana Nkya, Sheryl McCurdy, Columba Mbekenga, Karim Manji, Michael Parker, Julie Makani

    The prevalence of sickle cell disease is high in Africa, with significant public health effects on the affected countries. Many of the countries with the highest prevalence of the disease also have poor health care systems and a high burden of infectious diseases with many other competing health care priorities. Although considerable efforts have been made to implement newborn screening for sickle cell disease programs in Africa, coverage is still low. Tanzania has one of the highest birth prevalence of children with sickle cell disease in Africa. In 2015, the country implemented a pilot project for Newborn Screening for Sickle Cell Disease to assess feasibility. Several efforts have been made afterwards to continue providing the screening services as well as related comprehensive care services. Using qualitative methods, we conducted in-depth interviews and focus group discussions with policy makers (n = 4), health care providers (n = 21) and families (n = 15) to provide an analysis of their experiences and perspectives on efforts to expand and sustain newborn screening for sickle cell disease and related comprehensive care services in the country. Thematic content analysis was used to analyze the data through the framework analysis method. The findings have demonstrated both the opportunities and areas that need addressing in the implementation and sustainability of the services in low resource settings. A key area of strengthening is full integration of the services in countries’ health care systems to facilitate the coverage, accessibility and affordability of the services. Although the coverage of newborn screening services for sickle cell disease is still low, efforts at the local level to sustain the implementation of the programs and related comprehensive care services are encouraging and can be used as a model for other programs implemented in low resources settings.